Evidence map›Paper›PMID 40518457›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

The additive value of

Xuhao Liu, Lin Qi, Xiaomei Gao, Shuo Hu, Yongxiang Tang, Minfeng Chen, Yi Cai

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuhao LiuDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Lin QiDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Xiaomei GaoDepartment of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Shuo HuDepartment of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. hushuo2018@163.com.
Yongxiang TangDepartment of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. xyyf0401@qq.com.
Minfeng ChenDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. chenminfeng1999@csu.edu.cn.
Yi CaiDepartment of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. cai-yi@csu.edu.cn.ORCID 0000-0001-7773-2064

Funding

Outstanding Youth Fund Project of Hunan Province 500000
6 · The paper itself

Abstract

backgroundBesides its potential as a PET/CT tracer, the Gastrin-Releasing Peptide Receptor (GRPR) has been shown to predict the prognosis of Prostate Cancer (PCa). Herein, we aimed to evaluate the additive ability of

methodsThis retrospective single-center study involved patients who underwent both

resultsThis study involved 44 patients. Among them, 41 and 23 showed PSMA uptake and GRPR uptake, respectively, with 3 exhibiting GRPR uptake alone. The GRPR + group had an median PSA response rate of 37.78% and a median PFS duration of 8.9 months, both of which were significantly lower than those of GRPR- patients, whose corresponding values were 69.39% and 14.37 months, respectively. According to the multivariate analysis results, GRPR status, distant Lymph Node Metastasis (LNM) and PSMA SUVmax of bone metastases lesions were significant predictors of the PSA response rate. Furthermore, the GRPR status and PSMA SUVmax of regional lymph node metastases were significant predictors of PFS.

conclusionCompared to GRPR- patients, mCRPC patients with GRPR + lesions exhibited a lower median maximum PSA response rate and a shorter median PFS duration following ARSI treatment, implying a poorer response to therapy and relatively worse prognosis in the latter subgroup.

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingPositron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedProstate-Specific AntigenRetrospective StudiesTreatment OutcomeDipeptidesgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesHeterocyclic Compounds, 1-RingProstate-Specific AntigenPSMA-617ARSIGRPRmCRPCPrognosisPSMA

Identifiers

PMID40518457

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.